Basics CRISPR Therapeutics AG CRISPR Therapeutics AG is a gene editing company. It is engaged in the development of CRISPR/Cas9-based therapeutics. IPO Date: October 19, 2016 Sector: Healthcare Industry: Biotech Market Cap: $3.26B Activated in VL: True Average Daily Range Avg Daily Range: $1.63 | 2.81% Avg Daily Range (30 D): $1.27 | 3.58% Avg Daily Range (90 D): $1.09 | 2.75% Institutional Daily Volume Avg Daily Volume: 1.11M Avg Daily Volume (30 D): 2.14M Avg Daily Volume (90 D): 2.01M Trade Size Avg Trade Size (Sh.): 64 Avg Trade Size (Sh.) (30 D): 65 Avg Trade Size (Sh.) (90 D): 65 Institutional Trades Total Inst.Trades: 5,223 Avg Inst. Trade: $2.72M Avg Inst. Trade (30 D): $2.25M Avg Inst. Trade (90 D): $2.14M Avg Inst. Trade Volume: .04M Avg Inst. Trades (Per Day): 3 Market Closing Trades Avg Closing Trade: $4.87M Avg Closing Trade (30 D): $5.13M Avg Closing Trade (90 D): $5.1M Avg Closing Volume: 73.23K         News May 8, 2025 @ 3:22 PM Cathie Wood Goes Bargain Hunting: 3 Stocks She Jus... Source: Rick Munarriz Apr 20, 2025 @ 1:15 PM 5 Monster Stocks -- Such as Coupang -- to Hold for... Source: Selena Maranjian Apr 11, 2025 @ 7:45 AM Could CRISPR Therapeutics Become the Next Vertex P... Source: Adria Cimino Apr 8, 2025 @ 1:45 PM Is Vertex Pharmaceuticals Stock a Buy? Source: Dan Victor Apr 7, 2025 @ 12:09 PM 4 Beaten-Down Stocks That Could Skyrocket by 50% t... Source: Prosper Junior Bakiny Financials   TTM Q1 2025 Q4 2024 Basic EPS $-4.5 $-1.58 $-.42 Diluted EPS $-4.5 $-1.58 $-.42 Revenue $ 37.68M $ .87M $ 35.69M Gross Profit $ $ $ Net Income / Loss $ -385.66M $ -136M $ -37.31M Operating Income / Loss $ -474.4M $ -148.42M $ -64.59M Cost of Revenue $ $ $ Net Cash Flow $ -472.27M $ -63.11M $ 72.67M PE Ratio